Moreover, a recent study demonstrated that SHP-1 inhibition in combination with immune checkpoint blockade treatment (anti-PD1 and anti-CTLA4) increases the recruitment and the effectors’ function of low-affinity T cells, finally leading to melanoma tumor regression by increasing the frequency of IFN-γ-producing endogenous antitumor CD8+T cells [207]. The gene discussed is PTPN6; the disease is melanoma.